A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/ NgR / ROCK Signaling Pathway
CNS Neuroscience & Therapeutics · 2026-08 · 32 (8)
DOI: 10.1002/cns.71052 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 13.08.2026. Verfasst von Zheng Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong Province, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Signal Transduction, rho-Associated Kinases, Nogo Proteins. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Provincial Medical Science and Technology Research Fund.
Themen: Demenz
Abstract (Originalsprache)
Aims
To evaluate the therapeutic effects of NAP2, a novel NgR1 antagonist peptide, on Alzheimer's disease (AD) pathology and to determine whether inhibition of the Nogo‐A/NgR1/ROCK signaling axis can ameliorate neurodegenerative alterations in APP/PS1 mice.
Methods
APP/PS1 transgenic mice received a three‐month NAP2 intervention. Cognitive performance was assessed using standard learning and memory tests. Amyloid‐β plaque burden, dendritic spine density, tau phosphorylation, and Aβ42 levels were examined by histological and biochemical analyses. Mitochondrial function and downstream ROCK signaling activity were also evaluated.
Results
NAP2 treatment significantly improved cognitive performance in APP/PS1 mice. NAP2 reduced amyloid‐β plaque deposition, decreased Aβ42 expression, and increased hippocampal dendritic spine density. Tau hyperphosphorylation was notably attenuated. In addition, NAP2 alleviated Aβ42‐induced mitochondrial dysfunction. Mechanistic studies revealed that NAP2 interfered with ROCK signaling downstream of Nogo‐A.
Conclusion
NAP2 ameliorates multiple AD‐related pathological features, an effect accompanied by the inhibition of the Nogo‐A/NgR1/ROCK pathway. These findings highlight the therapeutic potential of NAP2 to enhance resilience against Alzheimer's disease pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, Guangdong Province, China.
- Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China.
- Department of Neurology, City Center Hospital of Zengcheng District in Guangzhou, Guangzhou, China.
- Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
- Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, Guangdong Province, China.
- Department of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
ORCID-Profile: Li-An Huang, Li Yan
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangdong Provincial Medical Science and Technology Research Fund
- 2024 Joint between City, University (College) and Enterprise
- Fundamental Research Funds for the Central Universities
- Horizontal Research from the Guangdong Provincial Health Economics Association
Zitieren
APA
Zhang, Z., Tan, H., Shi, F., Dai, J., Ding, W., Li, J., Wang, Y., Yang, R., Xu, X., Chen, C., Xiao, F., Huang, L. A., Liu, X., Liao, R., & Yan, L. (2026). A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/ NgR / ROCK Signaling Pathway. CNS Neuroscience & Therapeutics, 32(8). https://doi.org/10.1002/cns.71052
Vancouver
Zhang Z, Tan H, Shi F, Dai J, Ding W, Li J, et al. A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/ NgR / ROCK Signaling Pathway. CNS Neuroscience & Therapeutics. 2026;32(8). doi:10.1002/cns.71052
BibTeX
@article{Zhang2026,
author = {Zhang, Zheng and Tan, Huimin and Shi, Fang and Dai, Jiajia and Ding, Weilong and Li, Junliang and Wang, Yuke and Yang, Rui and Xu, Xinke and Chen, Cheng and Xiao, Fei and Huang, Li-An and Liu, Xiaoyan and Liao, Rui and Yan, Li},
title = {A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/ NgR / ROCK Signaling Pathway},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {8},
doi = {10.1002/cns.71052}
}
EUVIMED